SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 179 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $389,413 | +39.5% | 18,968 | +43.5% | 0.00% | 0.0% |
| Q1 2024 | $279,164 | -31.9% | 13,218 | -30.3% | 0.00% | 0.0% |
| Q4 2023 | $409,898 | +48.8% | 18,968 | 0.0% | 0.00% | 0.0% |
| Q3 2023 | $275,415 | -29.7% | 18,968 | +1.4% | 0.00% | 0.0% |
| Q2 2023 | $391,558 | +40.3% | 18,708 | +41.5% | 0.00% | 0.0% |
| Q1 2023 | $279,164 | -17.0% | 13,218 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $336,398 | +9.2% | 13,218 | +3.2% | 0.00% | 0.0% |
| Q3 2022 | $308,000 | +25.2% | 12,808 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $246,000 | +10.8% | 12,808 | +0.1% | 0.00% | – |
| Q1 2022 | $222,000 | -20.7% | 12,798 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $280,000 | +22.8% | 12,798 | +7.1% | 0.00% | – |
| Q3 2021 | $228,000 | +11.2% | 11,949 | 0.0% | 0.00% | – |
| Q2 2021 | $205,000 | -1.4% | 11,949 | +28.3% | 0.00% | – |
| Q1 2021 | $208,000 | +2.0% | 9,312 | +1.7% | 0.00% | – |
| Q4 2020 | $204,000 | – | 9,152 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $19,588,000 | 3.91% |
| Ghost Tree Capital, LLC | 575,000 | $10,988,000 | 3.21% |
| Avidity Partners Management LP | 4,823,400 | $92,175,000 | 2.04% |
| BVF INC/IL | 2,486,429 | $47,516,000 | 1.85% |
| FRAZIER MANAGEMENT LLC | 1,188,135 | $22,705,000 | 1.82% |
| Nantahala Capital Management | 2,657,159 | $50,778,000 | 1.60% |
| Boxer Capital, LLC | 2,287,782 | $43,720,000 | 1.53% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,939,000 | 1.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 750,603 | $14,344,000 | 1.20% |
| PFM Health Sciences, LP | 1,856,738 | $35,482,000 | 1.04% |